141 related articles for article (PubMed ID: 33099293)
1. Antiproliferative effects of [D-Pro2, D-Trp7,9]-Substance P and aprepitant on several cancer cell lines and their selectivity in comparison to normal cells.
Matalińska J; Świć A; Lipiński P; Misicka A
Folia Neuropathol; 2020; 58(3):237-244. PubMed ID: 33099293
[TBL] [Abstract][Full Text] [Related]
2. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo.
Berger M; Neth O; Ilmer M; Garnier A; Salinas-Martín MV; de Agustín Asencio JC; von Schweinitz D; Kappler R; Muñoz M
J Hepatol; 2014 May; 60(5):985-94. PubMed ID: 24412605
[TBL] [Abstract][Full Text] [Related]
3. Potential in vitro therapeutic effects of targeting SP/NK1R system in cervical cancer.
Mozafari M; Ebrahimi S; Darban RA; Hashemy SI
Mol Biol Rep; 2022 Feb; 49(2):1067-1076. PubMed ID: 34766230
[TBL] [Abstract][Full Text] [Related]
4. Blockade of slow excitatory post-synaptic potential by substance P antagonists in guinea-pig sympathetic ganglia.
Konishi S; Otsuka M
J Physiol; 1985 Apr; 361():115-30. PubMed ID: 2580973
[TBL] [Abstract][Full Text] [Related]
5. SP/NK1R system regulates carcinogenesis in prostate cancer: Shedding light on the antitumoral function of aprepitant.
Ebrahimi S; Mirzavi F; Aghaee-Bakhtiari SH; Hashemy SI
Biochim Biophys Acta Mol Cell Res; 2022 May; 1869(5):119221. PubMed ID: 35134443
[TBL] [Abstract][Full Text] [Related]
6. Differential consequences of neurokinin receptor 1 and 2 antagonists in metastatic breast carcinoma cells; Effects independent of Substance P.
Nizam E; Erin N
Biomed Pharmacother; 2018 Dec; 108():263-270. PubMed ID: 30223097
[TBL] [Abstract][Full Text] [Related]
7. The antiproliferative action of [D-Arg(1), D-Phe(5), D-Trp(7,9), LEU(11)] substance P analogue antagonist against small-cell- and non-small-cell lung cancer cells could be due to the pharmacological profile of its tachykinin receptor antagonist.
Munoz M; Recio S; Rosso M; Redondo M; Covenas R
J Physiol Pharmacol; 2015 Jun; 66(3):421-6. PubMed ID: 26084224
[TBL] [Abstract][Full Text] [Related]
8. Effects of intranigral substance P and neurokinin A on striatal dopamine release--I. Interactions with substance P antagonists.
Reid MS; Herrera-Marschitz M; Hökfelt T; Ohlin M; Valentino KL; Ungerstedt U
Neuroscience; 1990; 36(3):643-58. PubMed ID: 1700329
[TBL] [Abstract][Full Text] [Related]
9. Radiochemical Synthesis and Evaluation of Novel Radioconjugates of Neurokinin 1 Receptor Antagonist Aprepitant Dedicated for NK1R-Positive Tumors.
Halik PK; Lipiński PFJ; Matalińska J; Koźmiński P; Misicka A; Gniazdowska E
Molecules; 2020 Aug; 25(16):. PubMed ID: 32824729
[TBL] [Abstract][Full Text] [Related]
10. The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.
Coveñas R; Rodríguez FD; Robinson P; Muñoz M
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958914
[TBL] [Abstract][Full Text] [Related]
11. The SP/NK1R system promotes the proliferation of breast cancer cells through NF-κB-mediated inflammatory responses.
Jafarinezhad S; Assaran Darban R; Javid H; Hashemy SI
Cell Biochem Biophys; 2023 Dec; 81(4):787-794. PubMed ID: 37740877
[TBL] [Abstract][Full Text] [Related]
12. Targeting the neurokinin-1 receptor inhibits growth of human colon cancer cells.
Garnier A; Vykoukal J; Hubertus J; Alt E; von Schweinitz D; Kappler R; Berger M; Ilmer M
Int J Oncol; 2015 Jul; 47(1):151-60. PubMed ID: 25998227
[TBL] [Abstract][Full Text] [Related]
13. Interaction of substance P antagonists with substance P receptors on dispersed pancreatic acini.
Jensen RT; Jones SW; Lu YA; Xu JC; Folkers K; Gardner JD
Biochim Biophys Acta; 1984 Jun; 804(2):181-91. PubMed ID: 6202326
[TBL] [Abstract][Full Text] [Related]
14. Effects of the substance P antagonist, (D-Arg1, D-Pro2, D-Trp7,9, Leu11)-SP on the miotic response to substance P, antidromic trigeminal nerve stimulation, capsaicin, prostaglandin E1, compound 48/80 and histamine.
Mandahl A; Bill A
Acta Physiol Scand; 1984 Jan; 120(1):27-35. PubMed ID: 6202097
[TBL] [Abstract][Full Text] [Related]
15. Solution conformation of Substance P antagonists-[D-Arg1, D-Trp7,9, Leu11]-SP, [D-Arg1, D-Pro2, D-Trp7,9, Leu11]-SP and [D-Pro2, D-Trp7,9]-SP by CD, NMR and MD simulations.
Prabhu A; Malde A; Coutinho E; Srivastava S
Peptides; 2005 May; 26(5):875-85. PubMed ID: 15808918
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the antileukemic effects of neurokinin-1 receptor antagonists, aprepitant, and L-733,060, in chronic and acute myeloid leukemic cells.
Dikmen M; Gökhaner G; Cantürk Z
Anticancer Drugs; 2019 Aug; 30(7):e0769. PubMed ID: 31306152
[TBL] [Abstract][Full Text] [Related]
17. In the eye (D-Pro2, D-Trp7,9)-SP is a substance P agonist, which modifies the responses to substance P, prostaglandin E1 and antidromic trigeminal nerve stimulation.
Mandahl A; Bill A
Acta Physiol Scand; 1983 Jan; 117(1):139-44. PubMed ID: 6190353
[TBL] [Abstract][Full Text] [Related]
18. The Effect of Blocking Neurokinin-1 Receptor by Aprepitant on the Inflammatory and Apoptosis Pathways in Human Ovarian Cancer Cells.
AlAlikhan A; Ghahremanloo A; Javid H; Ebrahimi S; Hashemy SI
Cell Biochem Biophys; 2022 Dec; 80(4):819-827. PubMed ID: 36197642
[TBL] [Abstract][Full Text] [Related]
19. The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines.
Muñoz M; Rosso M; Robles-Frias MJ; Salinas-Martín MV; Rosso R; González-Ortega A; Coveñas R
Lab Invest; 2010 Aug; 90(8):1259-69. PubMed ID: 20458280
[TBL] [Abstract][Full Text] [Related]
20. Antagonism by (D-Pro2, D-Trp7,9)-substance P of the cerebrovascular dilatation induced by substance P.
Edvinsson L; McCulloch J; Rosell S; Uddman R
Acta Physiol Scand; 1982 Dec; 116(4):411-6. PubMed ID: 6189366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
